FACILITATING DEVELOPMENT OF NOVEL TREATMENTS

Partners

Immune Design is committed to exploiting the full potential of its product development capabilities. While our primary focus is on the development of immuno-oncology therapies, we also establish collaborative partnerships to develop potential treatments for non-oncology diseases, such as infectious and allergic diseases. We look to our partnerships to provide potential downstream economics while preserving growth opportunities in the future.

Corporate Partners

sanofi

Immune Design entered into a license agreement with Sanofi for use of Immune Design’s GLAAS™ discovery platform to develop therapeutic agents to treat peanut food allergy. Under an existing collaborative research arrangement, Sanofi and Immune Design have generated a large set of preclinical data demonstrating that certain formulations within GLAAS, when given prophylactically or therapeutically, can shift the immune responses in a way that may result in significant protection and reduction from allergy symptoms. In September 2016, we announced the first clinical application of our GLAAS discovery platform in Sanofi’s Phase 1 clinical trial evaluating a novel therapeutic candidate for the treatment of peanut allergy. We received an undisclosed milestone payment for start of the trial, and are eligible to receive future development and commercialization milestones, as well as tiered royalties on sales of approved products.
Sanofi.us
(See Press Release)

MedImmune

Immune Design has two license agreements with MedImmune, the worldwide biologics unit for AstraZeneca PLC , for the use of the GLAAS™ platform to discover, develop and commercialize products treating respiratory syncytial virus, or RSV, and an additional undisclosed indication. The RSV program is currently in Phase 2 clinical development.
Gaithersburg, MD
medimmune.com
(See Press Release)

 

Immune Design and Sanofi Pasteur, the vaccines division of Sanofi, entered into a broad collaboration for the development of a herpes simplex virus (HSV) immune therapy. Each company has contributed product candidates to the collaboration: Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine product candidate. The collaboration will explore the potential of various combinations of agents, including leveraging Immune Design’s GLAASTM platform, with the goal to select the best potential immune therapy for patients.
www.sanofipasteur.com

Clinical Collaborations

merck

Immune Design entered into clinical collaboration agreements with Merck, known as MSD outside the U.S. and Canada, to evaluate the safety and efficacy of two Immune Design immuno-oncology investigative agents, G100 and LV305, separately combined with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in Phase 1 trials in patients with non-Hodgkin’s lymphoma (NHL) and melanoma, respectively. One clinical trial is examining intratumoral administration of G100 with intravenous administration of KEYTRUDA in patients with follicular NHL receiving local radiation. In addition to an evaluation of the safety of the combination, the study will assess the response in both injected and non-injected lesions. The other clinical trial in melanoma is evaluating safety and response to the combination of LV305 and KEYTRUDA in patients who have not yet responded to treatment with KEYTRUDA alone after three months of treatment.
(See Press Release)

genetech

Immune Design entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of its CMB305 cancer immunotherapy product candidate combined with the investigational cancer immunotherapy atezolizumab in a randomized Phase 2 trial in patients with soft tissue sarcoma. Atezolizumab is a PD-L1 antagonist and is designed to block inhibitory T-cell checkpoints and allow cytotoxic T cells to reach the tumor. The randomized, open label Phase 2 trial is ongoing and evaluating CMB305 and atezolizumab in patients with locally advanced, relapsed, or metastatic synovial sarcoma or myxoid/round-cell liposarcoma, two types of sarcoma that tend to express NY-ESO-1 broadly.
(See Press Release)